A B S T R A C T Three different multicomnpartmental models of free fatty acid (FFA) and very low density lipoprotein triglyceride fatty acid (VLDL-TGFA) transport in man are formulated from plasma FFA and VLDL-TGFA tracee and tracer data collected over a 24 hr interval after the injection of palmitate-"C. All modeling and data fitting were performed on a digital computer using the SAAM program. Structural differences in the three models relate to the position of the slowly turning over compartment required to generate the late portion of the plasma VLDL-TGFA tracer data. The positions of this slow compartment are along the hepatic pathway from FFA to VLDL-TGFA (model A) or in the distribution system of VLDL-TGFA (model B) or in the distribution system of FFA (model C). Although all three models are equally consistent with our experimental data and are supported by observations of others, each reveals inconsistency with some data obtained from the literature. heterogeneity of the plasma VLDL-TGFA pool, and contamination of plasma VLDL-TGFA radioactivity with low density lipoprotein (LDL) TGFA radioactivity were tested. The first model does not explain the late portion of the plasma VLDL-TGFA tracer data. The second and third models, while consistent with our tracee and tracer data, have steady-state implications with respect to the extent of kinetic heterogeneity and size of the LDL-TGFA contaminant that make them unlikely.
INTRODUCTION
During the last 10 yr several quantitative models have been proposed to describe plasma free fatty acid (FFA) and triglyceride fatty acid (TGFA) transport in man. Most of these models have been based on the responses of labeled lipid moieties in the plasma following the injection or infusion of radioactive glycerol, FFA or TGFA. Farquhar, Gross, Wagner, and Reaven (1) and Nestel (2) injected glycerol-'H and FFA-14C, respectively, and estimated the production rate of TGFA in very low density lipoprotein (VLDL) from measurements of plasma VLDL-TGFA specific activity (SA). to estimate the extent of FFA incorporation into TGFA. It was based on plasma FFA and TGFA SA data obtained during a continuous infusion of FFA-14C. Havel (7) modified this method (Havel model II) and also obtained SA data on FFA and VLDL-TGFA in hepatic vein blood to allow a better estimate of the production rate of VLDL-TGFA (Havel model I). A multicompartmental model based on SA of plasma FFA and total TGFA collected over a 4 hr interval was formulated by Eaton, Berman, and Steinberg (8) to estimate several measures of FFA and TGFA transport. Some of these approaches to FFA-TGFA kinetics were recently reviewed by Baker (9) .
Quarfordt et al. (10) have continued the investigations of Eaton et al. (8) in normal and hypertriglyceridemic subjects on normal and high carbohydrate diets. They measured specifically the SA of TGFA in plasma VLDL and extended their observations over a 24 hr interval following the injection of palmitat24C. To deal with these latest studies and others in the literature, the model of Eaton et al. (8) is developed further in this report. Several different compartmental models are formulated that are equally consistent with the experimental data but have different physiological implications. These implications are carefully analyzed in an attempt to determine the applicability of each model to lipid transport in man. The results of this analysis suggest additional experiments that might clarify those measures of lipid transport which remain quantitatively uncertain. An attempt is made to explain some of the wide variation in estimates of measures of lipid transport reported by different groups of investigators.
DEVELOPMENT OF COMPARTMENTAL MODEL A. Physiological considerations. A schematic inputoutput diagram of the basic metabolic pathways considered in construction of the model are shown in Fig. 1 .
Plasma FFA are mainly derived from extravascular sources (primarily adipose tissue), although some may come directly from intravascular hydrolysis of esterified fatty acids contained in plasma lipoproteins. Pathways taken by FFA leaving the plasma include hepatic and extrahepatic esterification, exchange with extravascular pools (extracellular and intracellular), and tissue oxidation to C02. A fraction of the plasma FFA extracted by the liver and of the fatty acid synthesized de novo in the liver is oxidized to C02 or ketone bodies, and some is subsequently secreted into the plasma as VLDL-TGFA. Pathways for plasma VLDL-TGFA include uptake by peripheral tissues, conversion to other plasma lipoproteins, and recycling to liver or to plasma FFA.
B. Kinetic considerations: qualitative. To be acceptable a model must be compatible with all of the kinetic data available from many sources. These include data on plasma FFA-14C, plasma VLDL-TGFA-14C, and 14CO2 expiration after the injection or infusion of palmitate-&4C. Other important constraints are imposed by the requirement that steady-state calculations for pool sizes of plasma FFA and VLDL-TGFA and hepatic TGFA and for the rate of total CO excretion must be compatible with observed or estimated values. Taking all of these factors into account, three models were formulated and tested against experimental data (models A, B, and C in Fig. 1 of the companion paper).' Symbols used to describe model parameters and various composite measures of these parameters are defined in Table I .
The basis for the compartmental structure of the three models can be readily understood in qualitative terms by careful attention to the shapes of plasma FFA 'All three models are equally consistent with our plasma FFA and VLDL-TGFA tracer and tracee data, yet each has distinct physiological implications relating to the position of the slowly turning over compartment (dashed circles). and VLDL-TGFA SA curves obtained after the injection of palmitate-14C. A typical set of such data from a normal subject (study 1A in companion paper) is presented in Fig. 2 . The biexponential function required to fit the FFA tracer data over 90 min implies exchange of plasma FFA with at least one other compartment (compartment 2 in models A, B, and C) (10) . The VLDL-TGFA tracer data exhibit an initial time delay before any significant activity is observed in the plasma VLDL-TGFA pool. This delay has been previously noted by Baker and Schotz (11) in the rat and by Eaton et al. (8) in man. The VLDL-TGFA tracer data also exhibit a flattening at the top of the curve as well as a further delay in the time (tmax) at which maximum activity is reached. The tman value in some patients with hypertriglyceridemia can occur as late as 240 min (10) .
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Both of these features of the VLDL-TGFA tracer curve (flattening at top and delayed t...) suggest that plasma FFA enroute to VLDL-TGFA mix in an intermediate hepatic pool turning over more slowly than that producing the initial delay before VLDL-TGFA activity appears in the plasma. This intermediate hepatic pool is introduced in all three models as compartment 4 ( Fig.   1 of the companion paper).' After tnax the VLDL-TGFA plasma activity initially disappears in what appears to be a first-order fashion. However, a slow component clearly emerges beyond 500 min. This slow component has been found by all investigators who have carried out observations over a long enough time interval (1, 2, 10, 12) . Extensive testing of various models showed that the slow component can be generated by a slowly turning over compartment (hashed circles of Fig. 1 of the companion paper) positioned either in the FFA distribution system (model C), along the hepatic pathway from FFA to VLDL-TGFA (model A), or in the distribution system of VLDL-TGFA (model B). Each one of these three positions has distinct physiological implications and forms the basis for the differences among models A, B, and C.
C. Kinetic considerations: quantitative. Using the SAAM digital computer program (13, 14) , an attempt was made to fit model A to the tracer and tracee data shown in Fig. 2 . It was found that the model was nonunique, i.e., certain parameters could assume a wide range of values and still fit the data equally well (15) . To obtain uniqueness the following statistical constraints were imposed on the parameters of the model: (a) XS,4 =0.0150 min' +20%, (b) X1,2 = 0.0175 min' ±20%.
The value of X5,4 in constraint 1 was chosen as a population mean after trying various values ranging from 0.005 min' to 0.05 min'. Values of X5,4 between 0.01 min' and 0.02 min' generated a degree of flattening at the top of the VLDL-TGFA tracer curve and delay in tran most consistent with data from all the normal and hyperglyceridemic studies in the present series (10) . Effects of changes in X5,4 on the values of other parameters in the model are discussed under Model Testing.
The second constraint was required because of the inability to determine uniquely the slope of the second exponential component of the plasma FFA tracer data. A value for X1,2 was therefore chosen to be consistent (within the statistical limits defined) with the plasma FFA tracer data obtained by Eaton et al. (8) The excellent fit of computer-generated data (using model A) to the experimental data of study 1A is shown in Fig. 2 . Models B and C were then evaluated using the theoretical data simulated from the calculated least squares fit of model A to the experimental data. This was done to avoid eliciting differences in parameter values among models A, B, and C that might be related only to random fluctuation of the experimental data. By analyzing the experimental data with respect to the three models in this way, differences in the parameter values shown below are due entirely to the intrinsic structural differences of the three models. Models B and C fit the theoretical data simulated from model A within about 1%. In other words, with appropriate values for rate constants, the three models shown in Fig. 1 of the companion paper are all equally compatible with the experimental data. Parameter values, measures derived from them, and estimated uncertainties for models A, B, and C are shown in Table II . The estimates of uncertainties for models B and C are based on an assumed 5% random fluctuation in the theoretical data. Any choice among these models must be based, then, on data other than those shown in Fig. 2 ences among the three models and the bases for choosing among them. D. Comparison of parameters and steady-state solutions of models A, B, and C. Parameter differences having particular physiological significance in the three models (Table II) include X,,s (fractional rate of hepatic uptake of plasma FFA enroute to plasma VLDL-TGFA) and o0,5 (fractional rate of irreversible loss of plasma VLDL-TGFA activity). Since in models B and C there is no slowly turning over compartment in the synthetic pathway between plasma FFA and VLDL-TGFA, x3,1 is about half the value obtained with model A. In models A and C the values for 50,5 are similar.
However, in B, .5o,s is only about one-half the value found in A and C. This difference arises from the fact that about one-half of the plasma VLDL-TGFA activity in B does not leave the plasma irreversibly but recycles through compartment 7 back to the plasma at a later time. Consequently, the sum of , 5 õs and .7,5 in B (total fractional turnover rate of VLDL-TGFA) is similar to .50,5 alone in models A and C. The rate constants for the slowly turning over compartments required to produce the late, portion of the VLDL-TGFA activity curve (significant radioactivity still present at 1440 min) are the smallest in magnitude (X5s in A, X5,7 in B, and X1,s in C).
These B. Effects of parameter changes in model A on parameters of models B and C. In the companion paper (10) certain changes in the parameters of model A (mainly X32, Xo.5) are reported in subjects on highcarbohydrate diets and in patients with type IV hyperlipoproteinemia. Corresponding changes (due to diet and disease) on the parameters of model B and C were also investigated. It was important in eliciting changes in parameter values to avoid effects due to the random fluctuations in the experimental data. (See Development of Compartmental Model-section C). Hence, using model A fitted to subject 1A as a reference model, sets of VLDL-TGFA tracer and steady-state data were simulated to correspond to certain parameter changes in model A, and the theoretical data thus derived were fitted to models B and C subject to the constraints The following parameter changes were introduced in model A: (1) Xe,1 increased by 50% with a corresponding 50% increase in M5 (the sum X3,1+ Xoi was kept constant to keep the plasma FFA SA curve unchanged); (2) X0,5 was decreased 50% with a corresponding 100% increase in Me; (3) the ratio p54/pee (a) decreased from 0.52 to 0.30 with M5 unchanged. The effects these changes would have on VLDL-TGFA SA curves are shown in Fig. 3 .
Changes in the parameters and steady-state measures in models B and C due to perturbation (1) in model A Table V Consequently the ratio of Ao,s/AXo, + A7,5) in B is nearly Physiological implications of models A, B, and C All three models presented are equally consistent with the experimental data (tracer and tracee). However, differences in position of the slow compartment of each model lead to quite different physiological implications.
Model C suggests that the plasma FFA activity response to an injection of FFA-14C can be described by a triexponential equation in which the slowest exponential, becoming dominant sometime after 4 hr, has a half-time greater than 10 hr (Table II) . This triexponential response is qualitatively consistent with the FFA tracer data obtained in man by Fredrickson and Gordon (16) . Model C, however, requires that a significant portion of plasma VLDL-TGFA (> 40%) be derived from fatty acid sources other than plasma FFA, i.e., U5. This seems unlikely in view of the in vivo human studies performed by Havel (7) and Fine et al. (18) . Havel (7) and Eaton et al. (8) or the studies of Havel et al. (19) and Laurell (25) in the rabbit and rat, respectively.
A third problem with models A and C is the fact that they do not take into account any direct hepatic uptake of plasma VLDL-TGFA as suggested by Havel et al. (19) in the rabbit and Stein and Shapiro (26) in the rat.
'The calculated hepatic esterified fatty acid mass of the sum of the delay compartments and compartment 4 did not exceed 2 g in any of our normal or hypertriglyceridemic subjects (10) . Consequently, the total mass of the hepatic esterified fatty acid pool through which the`4C moves before being secreted is close to Ma. consistent with the pertinent data from the literature mentioned above as well as the data shown in Fig. 2 . Unfortunately, available experimental data in man are inadequate to resolve uniquely the three slowly turning over compartments of such a combination model.
Other models of plasma FFA and VLDL-TGFA transport A. Recycling of plasma VLDL-TGFA through the plasma FFA pool. It has been suggested by Eaton et al. (8) that about 60% of total plasma TGFA may be converted to plasma FFA through a relatively fast pathway. It could be hypothesized that this recycling of plasma TGFA through the plasma FFA pool could account for the late portion of the plasma VLDL-TGFA activity curve as opposed to compartments 6, 7, and 8 in models A, B, and C, respectively. This hypothesis was tested using model D (Fig. 4) , a variant of model C without compartment 8. In model D, X1.5 and Xo,5 are set equal to 60% and 40%, respectively, of the value of Xo,6 in C. All other parameters remain unchanged. Model E, also shown in Fig. 4 is a further modification of model C without compartment 8. Here recycling of plasma VLDL-TGFA to plasma FFA takes place through a slowly turning over compartment 9. In model E, X9,5 and Xe,9 are set equal to X1,5 in D and X1,s in C, respectively. This insures that the slope of the late portion of the FFA curve generated by model E will be similar to that generated by C. Fig. 5 reveals, however, that the magnitude of the late portion of the FFA SA curve generated by model E is less than 10% of that required to produce the proper magnitude of the late portion of the plasma VLDL-TGFA SA curve generated by model C. Furthermore, data obtained by Eaton et al. (8) on the transport of total plasma TGFA to plasma FFA do not suggest movement through a slowly turning over pathway such as compartment 9. Thus, the late portion of the plasma VLDL-TGFA SA data, occurring between 8 and 24 hr following a pulse injection of FFA-"C, is not explained satisfactorily by recycling of plasma VLDL-TGFA through the plasma pool. However, significant recycling of plasma VLDL-TGFA through the plasma FFA pool, if superimposed on models A, B, or C, would be consistent with the data of Fig. 2 and is supported by the data of Eaton et al. (8) .
B. Kinetic heterogeneity of the plasma VLDL-TGFA pool. There is little or no direct evidence in man suggesting kinetic heterogeneity within the plasma VLDL-TGFA pool. However, such heterogeneity would be consistent with the biexponential plasma disappearance curve of injected labeled VLDL-TGFA (7). Consequently, VLDL-TGFA kinetic heterogeneity was investigated using models F and G (Fig. 6 ). Both models are variants of model B (Fig. 1 of the FIGURE 6 Two models describing kinetic heterogeneity of the plasma VLDL-TGFA pool.
Model F assumes that the liver secretes two kinetically distinct species of VLDL-TGFA of widely different fractional turnover rates. Model G assumes that the liver secretes a relatively rapidly turning over species of VLDL-TGFA which is partially converted in the plasma into a much more slowly turning over species of VLDL-TGFA.
fractional turnover rate (Xo,5) similar to X5,5 of model B, while the other species (compartment 5') has a much smaller fractional turnover rate (X.,5 ) equal to about one-half the value of X5,7 of model B. Model G assumes that a relatively rapidly turning over species of VLDL-TGFA (compartment 5) is secreted by the liver and partially converted in the plasma into a much more slowly turning over species of VLDI-TGFA (compartment 5'). Values of Xo,6 and xo,5' of model G are nearly equal to Xo,5 and Xo,5' of model F.
Both models were consistent with the tracer and tracee data of Fig. 2 . Steady-state solution of both reveals that the slowly turning over species of VLDL-TGFA (responsible for the late portion of the VLDL-TGFA data) accounted for about 50% of the total plasma VLDL-TGFA mass and 2.5% of the total plasma VLDL-TGFA transport. Although these two models (and variants of them) cannot be ruled out on the basis of the data of Fig. 2 , their steady-state implications with respect to the ratios of M5/M5I (about 1) and Po,5/po.5' (about 40) are not supported by any available evidence.
It might be hypothesized that the late portion of the plasma VLDL-TGFA tracer data (Fig. 2) represents contamination of VLDL-TGFA with the more slowly turning over LDL-TGFA. Such contamination could be described by model G in which compartments 5 and 5' represent VLDL-TGFA and LDL-TGFA, respectively. Although consistent with the tracer and tracee data of Fig. 2 , the large size of M5' implied by model G argues against this hypothesis. Contamination of the late portion of the plasma VLDL-TGFA SA data by plasma FFA activity was negligible (10).
EXPERIMENTS SUGGESTED BY MODELS A, B, AND C An experiment that would help determine the quantitative significance of compartment 7 in model B and compartment 4 in models A, B, and C would be the injection of a labeled pulse of VLDL-TGFA. Observations of plasma VLDL-TGFA SA for 8-12 hr after such an injection would yield estimates of the size and minimum number of fatty acid pools exchanging with plasma VLDL-TGFA as well as help determine the relationship between compartments 4 and 5 in all three models. Such an experiment would also offer an upper limit estimate of the production rate of VLDL-TGFA. Monitoring the FFA SA over the same time interval would also help to determine the extent of plasma VLDL-TGFA recycling through the plasma FFA pool. Although similar experiments have been performed by Havel (7) and Eaton et al. (8) , the results have been ambiguous due to the short duration of the experiments and the heterogeneity of lipoprotein labeling, respectively.
The availability of high SA VLDL-TGFA would also allow a more definitive study of the possible existence of VLDL-TGFA kinetic heterogeneity. 4-8 hr after a pulse injection of labeled VLDL-TGFA, the VLDL-TGFA tracer could be aspirated from the plasma and reinjected. Significant kinetic heterogeneity of the plasma VLDL-TGFA pool would be considered unlikely if the plasma response to reinjected VLDL-TGFA tracer were similar to that resulting from the initial injection of labeled VLDL-TGFA. Important limitations of both of these reinjection experiments stem from the possible alterations of physical properties of VLDL resulting from the isolation techniques and the large quantities of radioactivity that would have to be injected into the donor subjects.
Another useful experiment to determine the necessity and significance of compartment 8 in model C would be the careful monitoring of plasma FFA SA for [8] [9] [10] [11] [12] hr after the injection of a pulse of FFA-14C. The problem of low FFA SA would have to be circumvented by use of larger doses of radioactivity and very careful isolation procedures for plasma FFA.
Given an independent estimate of total liver weight. the determination of hepatic TGFA SA by liver biopsy could also be helpful in estimating the hepatic TGFA mass and activity at a particular time. Such data, suggesting an upper limit for the total exchangeable hepatic esterified fatty acid mass, would impose constraints on the maximum sizes calculated for compartments 6 QUANTITATIVE COMPARISON OF MODELS A, B, AND C WITH OTHER MODELS Quantitative differences among the various models can best be brought out by applying each of the models to the same set of data. Choosing pTGaA as the measure for comparison, the data of the representative normal study shown in Fig. 2 were analyzed using the several models discussed above. The constant infusion response was simulated from the single injection data by convolution (28) . The SA ratio of plasma VLDL-TGFA to plasma FFA with respect to these simulated data was about 0. Table VII, were the hepatic vein FFA SA to be 20%o less than the antecubital vein FFA SA used in this analysis. PTGFA of models A and C would not change. However, p5,4 in both of these models would be increased by about 20% at the expense of a concomitant decrease in P5,, and U5 in models A and C, respectively. (2) and probably would fall within the minimal and maximal values of the range defined above. Quantitative differences elucidated in these models relate to some extent to the particular set of data evaluated. If the SA ratio of arterial VLDL-TGFA to hepatic vein FFA were greater at 4 hr than that implied by these data, differences in PTGFA among models A and C on one hand and model B and Havel model I on the other would have been less, and the range between minimal and maximal estimates of PTGFA would have been smaller. On the other hand these differences could have been greater were data from a hypertriglyceridemic patient used for the comparative analysis of PTGFA.
The wide range of estimates of PTGFA (15-80 iAEq min-') represents an example of how different kinetic models, all of which seem to be reasonable descriptions of the physiologic process (pTGoA), yield very different results even when applied to the same data. A number of explications for this disparity of estimates has been offered in terms of the more general logical framework of Transport of Plasma Free Fatty Acids and Triglycerides in Man models A, B, and C, within which the fundamental assumptions of other models have been evaluated.
